{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:55:43Z","timestamp":1787003743923,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T00:00:00Z","timestamp":1763856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100007834","name":"Ningbo Natural Science Foundation","doi-asserted-by":"crossref","award":["2023J323"],"award-info":[{"award-number":["2023J323"]}],"id":[{"id":"10.13039\/100007834","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Zhu Xiu Shan Talent Project of Ningbo No.2 Hospital","award":["2023HMJQ34"],"award-info":[{"award-number":["2023HMJQ34"]}]},{"name":"Zhejiang Province Clinical Key Specialty Construction Project","award":["2024023"],"award-info":[{"award-number":["2024023"]}]},{"name":"Ningbo Medical & Health Brand Discipline","award":["PPXK2024-04"],"award-info":[{"award-number":["PPXK2024-04"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-27504-w","type":"journal-article","created":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T05:24:00Z","timestamp":1763875440000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Optimization of thrombopoietin mimetic peptide fusion proteins with albumin-binding domain for enhanced bioactivity and extended half-life"],"prefix":"10.1038","volume":"15","author":[{"given":"Jingjing","family":"Ying","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutuo","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Airong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guosheng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,23]]},"reference":[{"issue":"4","key":"27504_CR1","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.3390\/ijms25042163","volume":"25","author":"A Mititelu","year":"2024","unstructured":"Mititelu, A. et al. Current understanding of immune thrombocytopenia: A review of pathogenesis and treatment options. Int. J. Mol. Sci. 25(4), 2163. https:\/\/doi.org\/10.3390\/ijms25042163 (2024).","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"27504_CR2","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1055\/s-0040-1701470","volume":"46","author":"H Al-Samkari","year":"2020","unstructured":"Al-Samkari, H. & Kuter, D. J. Immune thrombocytopenia in adults: Modern diagnosis and treatment. Semin. Thromb. Hemost. 46(3), 275\u2013288. https:\/\/doi.org\/10.1055\/s-0040-1701470 (2020).","journal-title":"Semin. Thromb. Hemost."},{"key":"27504_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.103820","volume":"76","author":"D Provan","year":"2022","unstructured":"Provan, D. & Semple, J. W. Recent advances in the mechanisms and treatment of immune thrombocytopenia. EBioMedicine 76, 103820. https:\/\/doi.org\/10.1016\/j.ebiom.2022.103820 (2022).","journal-title":"EBioMedicine"},{"issue":"1","key":"27504_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/nyas.14169","volume":"1466","author":"A Nakamura-Ishizu","year":"2020","unstructured":"Nakamura-Ishizu, A. & Suda, T. Multifaceted roles of thrombopoietin in hematopoietic stem cell regulation. Ann. N. Y. Acad. Sci. 1466(1), 51\u201358. https:\/\/doi.org\/10.1111\/nyas.14169 (2020).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"27504_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1260487","volume":"10","author":"MA Yassin","year":"2023","unstructured":"Yassin, M. A. et al. Thrombopoietin-receptor agonists for adult patients with immune thrombocytopenia: A narrative review. Front. Cardiovasc. Med. 10, 1260487. https:\/\/doi.org\/10.3389\/fcvm.2023.1260487 (2023).","journal-title":"Front. Cardiovasc. Med."},{"issue":"4","key":"27504_CR6","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s00277-023-05114-8","volume":"102","author":"D Pulani\u0107","year":"2023","unstructured":"Pulani\u0107, D. et al. Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: A systematic review and expert consensus. Ann. Hematol. 102(4), 715\u2013727. https:\/\/doi.org\/10.1007\/s00277-023-05114-8 (2023).","journal-title":"Ann. Hematol."},{"issue":"6","key":"27504_CR7","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.copbio.2011.08.007","volume":"22","author":"RE Kontermann","year":"2011","unstructured":"Kontermann, R. E. Strategies for extended serum half-life of protein therapeutics. Curr. Opin. Biotechnol. 22(6), 868\u2013876. https:\/\/doi.org\/10.1016\/j.copbio.2011.08.007 (2011).","journal-title":"Curr. Opin. Biotechnol."},{"key":"27504_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101777","volume":"56","author":"H Mei","year":"2022","unstructured":"Mei, H. et al. Efficacy and safety of treatments in newly diagnosed adult primary immune thrombocytopenia: A systematic review and network meta-analysis. eClinicalMedicine 56, 101777. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101777 (2022).","journal-title":"eClinicalMedicine"},{"issue":"10","key":"27504_CR9","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1038\/s41375-022-01669-z","volume":"36","author":"AS Kubasch","year":"2022","unstructured":"Kubasch, A. S. et al. Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms. Leukemia 36(10), 2519\u20132527. https:\/\/doi.org\/10.1038\/s41375-022-01669-z (2022).","journal-title":"Leukemia"},{"key":"27504_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2024.115334","volume":"210","author":"M Bern","year":"2024","unstructured":"Bern, M. et al. Albumin-based delivery systems: Recent advances, challenges, and prospects. Adv. Drug Deliv. Rev. 210, 115334. https:\/\/doi.org\/10.1016\/j.addr.2024.115334 (2024).","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"5","key":"27504_CR11","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1002\/bit.25158","volume":"111","author":"NE Levy","year":"2014","unstructured":"Levy, N. E. et al. Identification and characterization of host cell protein product-associated impurities in bioprocess development. Biotechnol. Bioeng. 111(5), 904\u2013912. https:\/\/doi.org\/10.1002\/bit.25158 (2014).","journal-title":"Biotechnol. Bioeng."},{"key":"27504_CR12","doi-asserted-by":"publisher","first-page":"1170357","DOI":"10.3389\/fimmu.2023.1170357","volume":"14","author":"Q Boder","year":"2023","unstructured":"Boder, Q. et al. Serum albumin binding knob domains engineered within a bispecific antibody format. Front. Immunol. 14, 1170357. https:\/\/doi.org\/10.3389\/fimmu.2023.1170357 (2023).","journal-title":"Front. Immunol."},{"key":"27504_CR13","doi-asserted-by":"publisher","DOI":"10.5936\/csbj.201303009","volume":"6","author":"J Nilvebrant","year":"2013","unstructured":"Nilvebrant, J. & Hober, S. The albumin-binding domain as a scaffold for protein engineering. Comput. Struct. Biotechnol. J. 6, e201303009. https:\/\/doi.org\/10.5936\/csbj.201303009 (2013).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"27504_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173650","volume":"890","author":"H Tan","year":"2021","unstructured":"Tan, H. et al. Albumin-binding domain extends half-life of glucagon-like peptide-1. Eur. J. Pharmacol. 890, 173650. https:\/\/doi.org\/10.1016\/j.ejphar.2020.173650 (2021).","journal-title":"Eur. J. Pharmacol."},{"key":"27504_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2023.106422","volume":"185","author":"Y Li","year":"2023","unstructured":"Li, Y. et al. Albumin-binding DARPins as scaffold improve the hypoglycemic activity of exenatide. Eur. J. Pharm. Sci. 185, 106422. https:\/\/doi.org\/10.1016\/j.ejps.2023.106422 (2023).","journal-title":"Eur. J. Pharm. Sci."},{"key":"27504_CR16","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1146\/annurev-pharmtox-010611-134654","volume":"55","author":"A Pl\u00fcckthun","year":"2015","unstructured":"Pl\u00fcckthun, A. Designed ankyrin repeat proteins (DARPins): Binding proteins for research, diagnostics, and therapy. Annu. Rev. Pharmacol. Toxicol. 55, 489\u2013511. https:\/\/doi.org\/10.1146\/annurev-pharmtox-010611-134654 (2015).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"5","key":"27504_CR17","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.3324\/haematol.2022.282209","volume":"108","author":"L Wang","year":"2023","unstructured":"Wang, L. et al. Targeting a thrombopoietin-independent strategy in the discovery of a novel inducer of megakaryocytopoiesis for thrombocytopenia. Haematologica 108(5), 1394\u20131411. https:\/\/doi.org\/10.3324\/haematol.2022.282209 (2023).","journal-title":"Haematologica"},{"issue":"10","key":"27504_CR18","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/j.addr.2012.09.039","volume":"65","author":"X Chen","year":"2013","unstructured":"Chen, X. et al. Fusion protein linkers: Property, design and functionality. Adv. Drug Deliv. Rev. 65(10), 1357\u20131369. https:\/\/doi.org\/10.1016\/j.addr.2012.09.039 (2013).","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"8","key":"27504_CR19","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/protein\/gzn028","volume":"21","author":"A Jonsson","year":"2008","unstructured":"Jonsson, A. et al. Engineering of a femtomolar affinity binding protein to human serum albumin. Protein Eng. Des. Sel. 21(8), 515\u2013527. https:\/\/doi.org\/10.1093\/protein\/gzn028 (2008).","journal-title":"Protein Eng. Des. Sel."},{"issue":"8","key":"27504_CR20","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1007\/s11095-011-0420-y","volume":"28","author":"YM Wang","year":"2011","unstructured":"Wang, Y. M. et al. Investigation of the pharmacokinetics of romiplostim in rodents with a focus on the clearance mechanism. Pharm. Res. 28(8), 1931\u20131938. https:\/\/doi.org\/10.1007\/s11095-011-0420-y (2011).","journal-title":"Pharm. Res."},{"key":"27504_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2024.105581","volume":"148","author":"S Qiu","year":"2024","unstructured":"Qiu, S. et al. Repeat dose and reproductive toxicity of thrombopoietin mimic peptide in Sprague-Dawley rats. Regul. Toxicol. Pharmacol. 148, 105581. https:\/\/doi.org\/10.1016\/j.yrtph.2024.105581 (2024).","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"1","key":"27504_CR22","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1080\/14712598.2024.2436094","volume":"25","author":"U Binder","year":"2025","unstructured":"Binder, U. & Skerra, A. Strategies for extending the half-life of biotherapeutics: Successes and complications. Expert Opin. Biol. Ther. 25(1), 93\u2013118. https:\/\/doi.org\/10.1080\/14712598.2024.2436094 (2025).","journal-title":"Expert Opin. Biol. Ther."},{"issue":"1","key":"27504_CR23","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41598-021-04560-6","volume":"12","author":"FY Nikravesh","year":"2022","unstructured":"Nikravesh, F. Y. et al. Extension of human GCSF serum half-life by the fusion of albumin binding domain. Sci. Rep. 12(1), 667. https:\/\/doi.org\/10.1038\/s41598-021-04560-6 (2022).","journal-title":"Sci. Rep."},{"issue":"8","key":"27504_CR24","doi-asserted-by":"publisher","first-page":"4246","DOI":"10.3390\/ijms25084246","volume":"25","author":"SM Deyev","year":"2024","unstructured":"Deyev, S. M. et al. Preclinical evaluation of HER2-targeting DARPin G3: Impact of albumin-binding domain (ABD) fusion. Int. J. Mol. Sci. 25(8), 4246. https:\/\/doi.org\/10.3390\/ijms25084246 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"27504_CR25","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jconrel.2016.03.004","volume":"228","author":"R Li","year":"2016","unstructured":"Li, R. et al. Fusion to an albumin-binding domain with a high affinity for albumin extends the circulatory half-life and enhances the in vivo antitumor effects of human TRAIL. J. Control Release 228, 96\u2013106. https:\/\/doi.org\/10.1016\/j.jconrel.2016.03.004 (2016).","journal-title":"J. Control Release"},{"issue":"5","key":"27504_CR26","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s10989-023-10559-6","volume":"29","author":"Z Shi","year":"2023","unstructured":"Shi, Z. et al. Genetically fused DARPins: A novel approach for designing extended-release thrombopoietin mimetic peptides. Int. J. Pept. Res. Ther. 29(5), 88 (2023).","journal-title":"Int. J. Pept. Res. Ther."},{"issue":"4","key":"27504_CR27","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/bab.1762","volume":"66","author":"SS Gapizov","year":"2019","unstructured":"Gapizov, S. S. et al. Fusion with an albumin-binding domain improves pharmacokinetics of an \u03b1v\u03b23-integrin binding fibronectin scaffold protein. Biotechnol. Appl. Biochem. 66(4), 617\u2013625. https:\/\/doi.org\/10.1002\/bab.1762 (2019).","journal-title":"Biotechnol. Appl. Biochem."},{"issue":"5","key":"27504_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.557","volume":"5","author":"Y Wang","year":"2024","unstructured":"Wang, Y. et al. Half-life extension of single-domain antibody-drug conjugates by albumin binding moiety enhances antitumor efficacy. MedComm 5(5), e557. https:\/\/doi.org\/10.1002\/mco2.557 (2024).","journal-title":"MedComm"},{"issue":"15","key":"27504_CR29","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.2147\/DDDT.S299591","volume":"26","author":"JB Bussel","year":"2021","unstructured":"Bussel, J. B. et al. A review of romiplostim mechanism of action and clinical applicability. Drug Des. Dev. Ther. 26(15), 2243\u20132268. https:\/\/doi.org\/10.2147\/DDDT.S299591 (2021).","journal-title":"Drug Des. Dev. Ther."},{"issue":"1","key":"27504_CR30","doi-asserted-by":"publisher","first-page":"26123","DOI":"10.1038\/s41598-024-76123-0","volume":"14","author":"H Wang","year":"2024","unstructured":"Wang, H. et al. Albumin binding domain fusion improved the therapeutic efficacy of human interleukin-2 variant with altered pharmacokinetic properties. Sci. Rep. 14(1), 26123. https:\/\/doi.org\/10.1038\/s41598-024-76123-0 (2024).","journal-title":"Sci. Rep."},{"issue":"17","key":"27504_CR31","doi-asserted-by":"publisher","first-page":"7565","DOI":"10.1007\/s00253-016-7447-2","volume":"100","author":"Y Ru","year":"2016","unstructured":"Ru, Y. et al. Expression and bioactivity of recombinant human serum albumin and dTMP fusion proteins in CHO cells. Appl. Microbiol. Biotechnol. 100(17), 7565\u20137575. https:\/\/doi.org\/10.1007\/s00253-016-7447-2 (2016).","journal-title":"Appl. Microbiol. Biotechnol."},{"issue":"5","key":"27504_CR32","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s10529-016-2049-8","volume":"38","author":"M Wang","year":"2016","unstructured":"Wang, M. et al. Functional expression of human serum albumin-tandem thrombopoietin mimetic peptide fusion protein as a novel thrombopoietin analog in Pichia pastoris. Biotechnol. Lett. 38(5), 779\u2013785. https:\/\/doi.org\/10.1007\/s10529-016-2049-8 (2016).","journal-title":"Biotechnol. Lett."},{"issue":"4","key":"27504_CR33","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1177\/1091581811404708","volume":"30","author":"E Knight","year":"2011","unstructured":"Knight, E. et al. Nonclinical safety assessment of a synthetic peptide thrombopoietin agonist: Effects on platelets, bone homeostasis, and immunogenicity and the implications for clinical safety monitoring of adverse bone effects. Int. J. Toxicol. 30(4), 385\u2013404. https:\/\/doi.org\/10.1177\/1091581811404708 (2011).","journal-title":"Int. J. Toxicol."},{"issue":"9","key":"27504_CR34","doi-asserted-by":"publisher","first-page":"14022","DOI":"10.1021\/acsnano.1c05922","volume":"15","author":"BM Chen","year":"2021","unstructured":"Chen, B. M. et al. Polyethylene glycol immunogenicity: theoretical, clinical, and practical aspects of anti-polyethylene glycol antibodies. ACS Nano 15(9), 14022\u201314048. https:\/\/doi.org\/10.1021\/acsnano.1c05922 (2021).","journal-title":"ACS Nano"},{"issue":"2","key":"27504_CR35","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/bab.2664","volume":"72","author":"\u0130 \u0130ncir","year":"2025","unstructured":"\u0130ncir, \u0130 & Kaplan, \u00d6. Escherichia coli in the production of biopharmaceuticals. Biotechnol. Appl. Biochem. 72(2), 528\u2013541. https:\/\/doi.org\/10.1002\/bab.2664 (2025).","journal-title":"Biotechnol. Appl. Biochem."},{"issue":"4","key":"27504_CR36","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.1007\/s11033-023-08324-5","volume":"50","author":"X Li","year":"2023","unstructured":"Li, X. et al. Improving pharmacological activities of thrombopoietin mimetic peptide by genetic fusion to albumin-binding domain. Mol. Biol. Rep. 50(4), 3301\u20133310. https:\/\/doi.org\/10.1007\/s11033-023-08324-5 (2023).","journal-title":"Mol. Biol. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27504-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27504-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27504-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T10:45:52Z","timestamp":1765363552000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27504-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,23]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["27504"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-27504-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,23]]},"assertion":[{"value":"19 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43542"}}